Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds.
Kymera Therapeutics Inc. (KYMR)
Market is closed
Sector: Investment Advice
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,460,000 | $176,810,200 | +26% | 2.76% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,995,929 | $164,108,577 | 1.82% | |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,161,801 | $141,278,493 | 5.76% | |
| 4. | Siren L.L.C. Raymond Debbane | 3,240,313 | $88,687,367 | +10% | 5% |
| 5. | Driehaus Capital Richard Driehaus | 1,168,791 | $31,989,810 | -16% | 0.31% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.00 | 58,780 | $2,586,320.00 | 353,412 | 2025-06-30 | Filing | |
| $44.00 | 115,783 | $5,094,452.00 | 2,219,858 | 2025-06-30 | Filing | |
| $44.00 | 142,604 | $6,274,576.00 | 2,798,795 | 2025-06-30 | Filing | |
| $44.00 | 600,309 | $26,413,596.00 | 6,117,295 | 2025-06-30 | Filing | |
| $44.00 | 55,191 | $2,428,404.00 | 534,134 | 2025-06-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.00 | 4,500 | $225,000.00 | 0 | 2025-06-11 | Filing | |
| $49.04 | 5,000 | $245,185.50 | 0 | 2025-06-03 | Filing | |
| $47.00 | 4,800 | $225,600.00 | 0 | 2025-06-03 | Filing | |
| $45.50 | 7,200 | $327,600.00 | 4,800 | 2025-06-03 | Filing | |
| $49.00 | 30,000 | $1,470,000.00 | 660,482 | 2025-06-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% |
News See All
Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader
B. Riley raised Kymera Therapeutics, Inc.’s (NASDAQ:KYMR) price target from $38 to $60, upgrading it from Neutral to Buy on June 3, 2025.
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT
On June 2, analyst Vikram Purohit from Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) with a price target of $49.
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating
On Monday, June 2, Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51
Earlier during the company's May 9 earnings call, Kymera indicated a strong financial position with $775 million in cash, which would extend the company's operational runway into H1 2028.
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621
On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript
Justine Koenigsberg: Good morning, and welcome to Kymera Therapeutics, Inc.'s Immunology Innovation Day, our virtual event to introduce our next immunology program, IRAF5.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript February 27, 2025Kymera Therapeutics, Inc. misses on earnings expectations.
Billionaire Hedge Funds
